Novartis entered into an agreement with Pfizer to acquire late-stage incontinence treatment Enablex® (darifenacin) a M3 antagonist in phase 3 for the treatment of overactive bladder. The deal could be worth up to US$225 M to Pfizer depending on certain marketing rights being obtained in US and Europe. Under the terms of the deal, Novartis gains all rights to Enablex®.